Skip to main content
Premium Trial:

Request an Annual Quote

Bioo Scientific Receives $500K NSF Grant to Develop RNAi-Delivery Tech

Premium

Bioo Scientific this week announced that it has received a two-year, $500,000 grant from the National Science Foundation to develop a targeted, in vivo RNAi-delivery technology.

The award, a phase II Small Business Innovation Research grant, will specifically fund Bioo Scientific's work on its so-called Targeted Transport Technology, which the company said involves linking an "RNAi-agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules.

"The RNAi agent-loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by" the antibody, Bioo Scientific added. "The RNAi agent is then released to reduce the expression of its intended target."

The company expects to use the technology to create RNAi-delivery products for use in animal research.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more